BAT Executive Dismisses Focus on Smoking Alternatives

Oct.12.2022
BAT Executive Dismisses Focus on Smoking Alternatives
BAT denies focus on smoking alternatives and plans to maximize growth from portfolio deployment. Transformation continues for a controversial industry.

The top executive of tobacco giant British American Tobacco (BAT) has rebuffed claims that the company will prioritize smoking alternatives, stating that such claims are too superficial.


Kingsley Wheaton, Chief Marketing Officer of British American Tobacco (BAT)


During an interview with City A.M., Chief Marketing Officer Kingsley Wheaton stated that although there may be "more advanced methods" for e-cigarette products in the northern hemisphere, this is driven solely by consumer demand and cigarette pricing.


Whittington stated that the deployment of BAT's investment portfolio, which includes Vuse and Glo, was aimed at achieving "maximum growth." He acknowledged that the tobacco industry remains "controversial" and that there is still a long way to go to achieve transformation. The company, which has a history of 120 years, has been undergoing a transformation plan to shift its customers from cigarette brands like Camel and Rothmans to its alternative products.


Wharton stated that, although growth of the company's new product line in markets such as South Africa, Kenya, and Pakistan has been slow, it is stable. The company is also attempting to identify suitable opportunities in developing markets.


Speaking to City A.M., Whitten said, "We need to provide scalable businesses and appropriate profits. Other regions in developing countries are taking advantage of this opportunity." He explained that some regions, such as Australia and Brazil, cannot achieve this due to strict regulations on tobacco alternatives.


He explained, "When cigarette prices rise, it becomes easier to distance oneself from the tobacco business." He cited the UK's success as an example, where 80% of the price of a pack of cigarettes is made up of taxes.


According to data from Action on Smoking and Health (ASH), the current number of smokers in the UK is five times that of 2012, accounting for approximately 8% of the total population.


Whittington stated that despite the fact that this FTSE 100-listed company's foray into e-cigarettes is still not profitable, it remains committed to its ambitious goal of new category tobacco comprising one-fifth of its overall revenue and profitability by 2025. For a company that serves 175 countries worldwide and generated over £25 billion in revenue in 2021, this goal may seem insignificant.


Statement:


This article is compiled from third-party sources and is intended for industry professionals for the purpose of exchanging and learning information.


This article does not represent the views of 2FIRSTS and 2FIRSTS is not able to confirm the authenticity or accuracy of the article's content. The translation of this article is solely for the purpose of industry communication and research.


Due to limitations in translation expertise, the compiled article may not express the same ideas as the original text. Please refer to the original text for accuracy.


2FIRSTS holds completely aligned positions with the Chinese government on any domestic, Hong Kong, Macau, Taiwan, and foreign-related expressions and stances.


The copyright of the compiled information belongs to the original media and authors. If there is any infringement, please contact us for removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Reuters: Big Tobacco Emerges as Winner After FDA Regulatory Shift
Reuters: Big Tobacco Emerges as Winner After FDA Regulatory Shift
According to Reuters, major tobacco companies may emerge as key beneficiaries after the U.S. FDA loosened regulations on vaping and nicotine pouch products, a shift that has sparked debate over public health risks.
Industry Insight
May.26
Altria and Juul Ask Court to Pause Antitrust Case Pending Ninth Circuit Review
Altria and Juul Ask Court to Pause Antitrust Case Pending Ninth Circuit Review
Altria and Juul are asking a California federal court to pause an antitrust case while they appeal a class certification ruling to the Ninth Circuit. The case alleges that Altria’s 2018 investment in Juul, a $12.8 billion deal for a 35% stake.
May.07 by 2FIRSTS.ai
Imperial Brands Explains What the UK Tobacco and Vapes Act 2026 Means for Retailers
Imperial Brands Explains What the UK Tobacco and Vapes Act 2026 Means for Retailers
Imperial Brands has outlined what the newly approved UK Tobacco and Vapes Act 2026 means for retailers. The legislation received Royal Assent on April 29, 2026, and gives the Government powers to extend tobacco-style regulation to a wider range of products, including vaping products, heated tobacco, nicotine pouches and cigarette papers. Imperial Brands emphasized that most measures will be introduced in phases rather than taking effect immediately.
May.11 by 2FIRSTS.ai
KT&G Q1 2026 Financial Results: Revenue at $1.156 Billion, E-Cigarettes to Launch Independent Overseas Expansion
KT&G Q1 2026 Financial Results: Revenue at $1.156 Billion, E-Cigarettes to Launch Independent Overseas Expansion
KT&G reports a 27.6% increase in Q1 operating profit, with traditional and new tobacco sectors driving growth.
May.07 by 2FIRSTS.ai
BAT New Zealand Says Illicit Tobacco Trade Drove Nearly 29% Revenue Decline in 2025
BAT New Zealand Says Illicit Tobacco Trade Drove Nearly 29% Revenue Decline in 2025
British American Tobacco New Zealand said the illicit tobacco trade is responsible for its profit halving and revenue falling between the 2024 and 2025 financial years. Financial results filed with the Companies Office show that BAT Holdings (New Zealand) recorded 2025 revenue of NZ$180.7 million, or about US$106.95 million based on the European Central Bank’s April 27, 2026 reference rates, down from NZ$254 million, or about US$150.33 million, in 2024.
Apr.28 by 2FIRSTS.ai
Brazilian Research Institutions Prepare Joint Recommendations on Electronic Smoking Device Studies
Brazilian Research Institutions Prepare Joint Recommendations on Electronic Smoking Device Studies
Brazil’s National Cancer Institute, the Oswaldo Cruz Foundation, and other research institutions are preparing a joint letter with recommendations and guidance for studies on electronic smoking devices, including e-cigarettes, vapes, and similar products. The guidelines were discussed on April 14 and 15 at the seminar “Building a Priority Research Agenda on Electronic Smoking Devices for Brazil” in Rio de Janeiro.
Apr.16 by 2FIRSTS.ai